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Background: The Hermansky–Pudlak Syndrome Type 4 (HPS4) gene, which encodes a subunit protein of the
biogenesis of lysosome-related organelles complex (BLOC)-3, which is involved in late endosomal trafficking, is
associated with schizophrenia; however, its clinical relevance in schizophrenia remains unknown. The purpose of
the present study was to investigate whether HPS4 is associated with cognitive functions in patients with
schizophrenia and healthy controls and with the clinical profiles of patients with schizophrenia.
Methods: We investigated the association of variants of HPS4 with clinical symptoms and cognitive function in Japanese
patients with schizophrenia (n = 240) and age-matched healthy control subjects (n = 240) with single nucleotide
polymorphisms (SNP)- or haplotype-based linear regression. We analyzed five tagging SNPs (rs4822724, rs61276843,
rs9608491, rs713998, and rs2014410) of HPS4 and 2–5 locus haplotypes of these five SNPs. The cognitive functions of
patients and healthy subjects were evaluated with the Brief Assessment of Cognition in Schizophrenia, Japanese-language
version, and the patients were assessed for their symptomatology with the Positive and Negative Symptom Scale (PANSS).
Results: In patients with schizophrenia, rs713998 was significantly associated with executive function under the dominant
genetic model (P = 0.0073). In healthy subjects, there was a significant association between working memory and two
individual SNPs under the recessive model (rs9608491: P = 0.001; rs713998: P = 0.0065) and two haplotypes (rs9608491-
713998: P = 0.0025; rs61276843-9608491-713998: P = 0.0064). No significant association was found between HPS4 SNPs and
PANSS scores or premorbid IQ, as measured by the Japanese version of the National Adult Reading Test.
Conclusions: These findings suggested the involvement of HPS4 in the working memory of healthy subjects and in the
executive function deficits in schizophrenia.
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Cognitive impairments are a core feature of schizophrenia
and a major determinant of functional outcome [1]. Cog-
nitive domains that are particularly impaired in patients
with chronic schizophrenia are verbal memory, working
memory, motor speed, verbal fluency, attention, and
executive function [2,3]. These cognitive domains, specif-
ically working memory and executive function, are* Correspondence: kazufuak@dokkyomed.ac.jp
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reproduction in any medium, provided the orheritable traits that have a potential association with gen-
etic variants [4,5]. Therefore, these traits are useful as an
intermediate phenotype to investigate the functional asso-
ciation of susceptibility genes for schizophrenia [6,7].
22q12 is one of the regions that show high logarithm
of the odds ratio scores in schizophrenia [8-10]. The
Hermansky–Pudlak Syndrome Type 4 (HPS4) gene
(OMIM: 606682) maps to human chromosome 22q12.1,
and it consists of 14 exons that span approximately 32 kb
of genomic DNA encoding an intracellular trafficking-
related cytoplasmic protein named HPS4 [11,12]. Theal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lar mass of 77 kDa and makes up BLOC-3 jointly with
HPS1 as a 1:1 heterodimer [13-15]. Hermansky–Pudlak
Syndrome (HPS; MIM: 203300) is a group of rare auto-
somal recessive diseases characterized by clinical symp-
toms, such as oculocutaneous albinism and bleeding
diathesis, and is caused by defective biogenesis of
lysosome-related organelles, such as melanosomes and
platelet-dense granules [16]. In our previous case–control
association study, haplotypes that were composed of five
tagging single-nucleotide polymorphisms (SNPs) of HPS4
(rs4822724, rs61276843, rs9608491, rs713998, and
rs2014410) were found to be significantly associated with
schizophrenia, a finding that was revealed by a sliding win-
dow approach for 2–5 locus haplotypes, including
rs9608491 as an essential SNP [17]. In addition, we have re-
ported that two Japanese siblings who suffered from the co-
morbidity of major mental disorders, schizophrenia and
major depression, and HPS harbored a nonsense mutation
in HPS4 [17].
HPS is caused by a mutation in one of the genes
named HPS1 to HPS9, which encode subunit proteins
that consist of multiprotein complexes, the adaptor pro-
tein complex-3 (AP-3), and the biogenesis of lysosome-
related organelles complex (BLOC)-1, 2, and 3 [18,19].
BLOC-1, BLOC-2, and AP-3 interact to play a pivotal
role in sorting and trafficking membrane proteins on
early endosomes [20-24]. Dysbindin, which is encoded
by the dystrobrevin binding protein 1 (DTNBP1) gene
(also known as HPS7), is one of the subunit proteins of
BLOC-1 [25]. Several lines of evidence from linkage, as-
sociation, and postmortem brain studies have indicated
an association between DTNBP1 and schizophrenia [26].
Genetic variants and haplotypes of DTNBP1 have fre-
quently been reported to be associated with a number of
cognitive functions, including verbal, visual, and general
memory [27-30], attention [31,32], and executive func-
tion [30,32], in patients with schizophrenia and/or
healthy controls. These genetic studies on DTNBP1
[26-32] led to several research studies on identification
of binding partners for dysbindin [21-24]. By contrast,
BLOC-3, which comprises HPS1 and HPS4, modulates
the intracellular movement and distribution of late
endosomes and lysosome-related organelles in cells
[14,15,33]. Although the precise function of BLOC-3 re-
mains to be clarified, the interaction between BLOC-3
and Rab GTPases has recently been found [34,35].
In order to investigate the association between puta-
tive candidate genes and cognitive impairments in
schizophrenia, a portable instrument with a high reliabil-
ity and validity is required to assess the cognition that is
specifically impaired in patients with schizophrenia.
Most of the neurocognitive assessment batteries that
have previously been used in schizophrenia studiesinvolve detailed assessments of the entire profile of
neuropsychological function, including normal function-
ing, but require lengthy and complex procedures. The
Brief Assessment of Cognition in Schizophrenia (BACS)
was developed as a neurocognitive battery that enables
brief administration (about 40 min) and portability and
has high reliability for specifically assessing the domains
of cognitive function that are consistently impaired in
schizophrenia, including verbal memory, working mem-
ory, motor speed, verbal fluency, attention, and executive
function [3,36]. The Japanese-language version of BACS
(BACS-J) has been developed for the assessment of cog-
nition in Japanese patients with schizophrenia, and its
reliability and validity have been confirmed [37].
To the best of our knowledge, HPS4 has not been re-
ported in relation to cognitive functions in patients with
schizophrenia or healthy controls. The aim of the present
study was to investigate whether HPS4 is associated with
cognitive functions in patients with schizophrenia and
healthy controls and with the clinical profiles of patients
with schizophrenia. We initially tested the association of
five tagging SNPs in HPS4 with the clinical profiles and
cognitive domains as measured by BACS-J in Japanese pa-
tients with schizophrenia, and the association of HPS4
SNPs with cognitive domains was also tested in healthy
controls. In addition, we examined the association of
HPS4 haplotypes and cognitive domains by using a sliding




This study included 240 patients with schizophrenia
(139 males/101 females; age = 48.1 ± 12.4, mean ± stand-
ard deviation) and 240 unrelated healthy controls (143
males/97 females; age = 48.0 ± 13.0) who were group-
matched for age and sex. The subjects in both groups
were aged 21–69 years and were recruited from the
Kanto area in Japan and included a substantial portion
of the subjects who were investigated in our previous
genetic study [17]. The patients with schizophrenia were
recruited from the Dokkyo Medical University School of
Medicine Hospital and affiliated hospitals, and all of
them met the Diagnostic and Statistical Manual of Men-
tal Disorders (DSM-IV) criteria [38] for a diagnosis of
schizophrenia. The onset and characteristic clinical course
of schizophrenia were confirmed by examination of the
medical chart. Only the patients with stable disease prior
to the neurocognitive assessments were included. There
were no specific medication criteria for exclusion of the
patient group with respect to the administration of anti-
psychotics, anticholinergic drugs, and benzodiazepines.
The healthy controls were unrelated volunteers who were
recruited mainly from nonprofessional university/hospital
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axis-I disorders. Across both groups, we excluded subjects
with a history of neurological disorders, significant head
injury, or significant drug or alcohol abuse. The objective
of the present study was clearly explained to the partici-
pants, and written informed consent was obtained from
all subjects in accordance with the Declaration of Helsinki
[39]. The study was formally approved by the Institutional
Review Board of the Ethical Committee of Dokkyo Medical
University School of Medicine.
Genotyping
We focused on genotyping five tagging SNPs (rs4822724,
rs61276843, rs9608491, rs713998, and rs2014410) in HPS4
because all the haplotypes are composed of these tagging
SNPs, with rs9608491 being included as an essential SNP
in the sliding window analysis of a window size of 2–5
SNPs, and these have been found to be associated with
schizophrenia in our previous case–control study [17].
Genomic DNA extraction and genotyping from the per-
ipheral blood samples that were collected from the total
subjects were performed as previously described [17]. In
brief, we extracted genomic DNA from the peripheral
blood samples with a QIAamp DNA Blood Maxi Kit
(QIAGEN Inc., Valencia, CA). Two SNPs (rs4822724 and
rs9608491) were genotyped with a TaqMan® assay (Assay
ID: C___2490761_10 and C__11747810_10, respectively,
Applied Biosystems, Foster City, CA) with a TP800 Dice
Real Time System (TaKaRa Bio Inc., Otsu, Japan). The
other three SNPs (rs61276843, rs713998, and rs2014410)
were genotyped with direct DNA sequencing of polymer-
ase chain reaction products with specific primer pairs, as
previously reported [17].
Clinical assessment
Smoking status and education years were self-reported
by the subjects. Information on the year of disease onset
was collected by chart review and double-checked by the
patient. Information regarding psychopharmacological
medication was collected by chart review. The dosages
of individual antipsychotics were gauged based on the
equivalent milligram dosage of haloperidol, and the in-
formation was summed for each patient and those of
anticholinergic drugs were gauged based on the dosage
of biperiden. The prescription status of anxiolytics/hyp-
notics was evaluated as a categorical variable. Patients
were assessed according to their clinical rating of symp-
tomatology of schizophrenia using the Positive and
Negative Symptom Scale (PANSS) [40].
Neurocognitive assessment
The cognitive functions were evaluated in the subjects
with version A of BACS-J [37]. The BACS-J cognitive
battery consists of the following six subtests that targetunique domains of cognition: list learning (verbal mem-
ory), a digit-sequencing task (working memory), a token
motor task (motor speed), category fluency and letter
fluency (verbal fluency), symbol coding (attention and
processing speed), and the Tower of London task (TOL;
executive function). The primary scores for each BACS-J
subtest were transformed into z-scores whereby the
healthy control mean was set to zero and it’s standard de-
viation to one. An overall composite score for global cog-
nition was generated by averaging all of the z-scores of
the six BACS-J subtests for individual participants. In
addition, the subjects were assessed with the Japanese ver-
sion of the National Adult Reading Test (JART) [41-43] to
measure the premorbid IQs of patients with schizophrenia
[44], with reference to a previous report that estimated
premorbid IQ with a Wide Range Achievement Test [36].
Statistical analysis
SPSS for Windows (version 19.0; IBM Japan, Tokyo,
Japan) was used for the statistical analysis. The differ-
ences in categorical variables (sex, smoking status, and
prescription status of anxiolytics/hypnotics) between pa-
tients with schizophrenia and healthy controls or be-
tween the genotype groups were analyzed using a chi-
square test. The demographic variables other than sex
and smoking status, the clinical variables of schizophre-
nia other than prescription status of anxiolytics/hyp-
notics, and the BACS-J subtest scores were regarded as
continuous variables and were assessed for normal dis-
tribution using a Shapiro–Wilk test (P < 0.05, implying a
nonnormal distribution). The differences between the
groups were analyzed with analyses of variance or with
the nonparametric Kruskal–Wallis and Mann–Whitney
U-tests if the variables showed a nonnormal distribution.
Departure from the Hardy–Weinberg Equilibrium was
analyzed for all SNPs using the exact test that was im-
plemented in PLINK version 1.0.7 [45,46]. SNPs with
P values less than 0.001 were considered to be in depart-
ure from the Hardy–Weinberg equilibrium, as described
by Saito et al. [17]. The standard measures of pair-wise
LD, denoted as D’ and r2, were estimated in Haploview
4.2 [47,48] based on the genotype data from all the
participants.
Prior to the SNP- or haplotype-based association ana-
lyses that used general linear models, age, education
years, JART-based premorbid IQ, and the BACS-J sub-
test scores, which showed nonnormal distributions, were
standardized and normalized across all of the subjects
with a mean of 0 and a variance of 1 using rank trans-
formation according to Blom’s method [49,50]. Associa-
tions between each HPS4 SNP and individual cognitive
domains were analyzed using a linear regression model
that was implemented in PLINK version 1.0.7 [45,46]
with the covariates of age, sex, education years, and
Table 1 Detailed descriptive data of patients with






Mean (SD) Mean (SD)
Age (years) 48.1 (12.4) 48.0 (13.0) -0.03 0.98
Sex (male, %)1 57.9 59.6 0.14 0.71
Education (years) 11.7 (2.1) 14.2 (2.3) -10.85 <0.001
Smokers (%)1 38.3 27.9 5.88 0.015
JART 92.4 (10.4) 103.4 (10.7) -10.19 <0.001
Age at onset (years) 24.8 (8.9) — — —
Antipsychotics (mg/day)2 12.7 (9.4) — — —
Anticholinergics (mg/day)3 3.3 (4.2) — — —
Anxiolytics/hypnotics (%) 75.4 — — —
PANSS
Positive score 14.1 (5.3) — — —
Negative score 21.9 (6.7) — — —
General score 33.9 (9.5) — — —
Total 69.0 (18.8) — — —
BACS-J scores
Verbal memory -2.01 (1.31) 0.00 (1.00) -14.63 <0.001
Working memory -1.95 (1.22) 0.00 (1.00) -14.67 <0.001
Motor speed -1.48 (1.26) 0.00 (1.00) -12.42 <0.001
Verbal fluency -1.15 (1.14) 0.00 (1.00) -10.62 <0.001
Attention -1.97(1.14) 0.00 (1.00) -15.41 <0.001
Executive function -1.77 (2.26) 0.00 (1.00) -9.67 <0.001
Composite Score -1.72 (1.10) 0.00 (0.67) -15.86 <0.001
P-values were analyzed using Mann–Whitney U-tests, except for 1χ2 tests.
P-values < 0.05 are in bold.
2Haloperidol equivalent dosage.
3Biperiden equivalent dosage.
BACS-J: Brief Assessment of Cognition in Schizophrenia,
Japanese-language version.
JART: Japanese version of the National Adult Reading Test.
PANSS: Positive and Negative Symptom Scale.
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performances were found to be affected by these con-
founding factors. The associations of each SNP with
cognitive domains were tested under the three following
genetic models that were fit for the minor alleles of each
SNP: dominant (comparing minor allele carriers with
major allele homozygotes), recessive (comparing minor
allele homozygotes with major allele carriers), and addi-
tive (assuming an allelic dosage effect of minor alleles by
coding none, one, or two copies of the minor allele as 0,
1, or 2, respectively). The associations of the haplotypes
with individual cognitive domains were analyzed using
haplotype-based association tests with a general linear
model that was implemented in PLINK version 1.0.7
[45,46] with the same covariates as were entered into
the single SNP-based association analysis. A sliding win-
dow approach with a window size of 2–5 SNPs was used
for the analysis. Haplotype frequencies were computed
using the standard expectation-maximization algorithm,
and haplotypes with a frequency of greater than 5% in
the whole sample were included in the analysis. A global
(or omnibus) P value was calculated to jointly estimate
all haplotype effects at the given locus. For both single
SNP- and haplotype-based association analyses, P values
were calculated by running 10,000 permutations using
the max (T) procedure to correct for multiple testing be-
tween SNPs or haplotypes by each BACS-J subtest. A
P value less than 0.0083 (0.05/6) was set as the threshold
for significance in order to correct for the number of
BACS-J subtests (six subtests) with Bonferroni correc-
tion. For haplotypes that met the significance criteria in
the global test, a haplotype-specific test was performed
to examine the independent effects of any estimated in-
dividual haplotypes by running 10,000 permutations in
order to correct for multiple testing between haplotypes
at the given locus.
Power analysis
A power analysis for linear regression was calculated by
G*Power 3.1.6 [51] using the Linear multiple regression:
Fixed model, R2 deviation from zero procedure, which pro-
vided power analyses for testing the null hypothesis that the
squared multiple correlation was zero [52,53]. Our cases
and controls (n = 240, for each group) had an 80% power to
detect an effect size of 0.08 or above at α = 0.0083.
Results
Association of HPS4 SNPs with cognitive domains
The detailed descriptive data for the patients with
schizophrenia and the healthy controls are shown in
Table 1. Both groups were well matched for age and sex.
The patients with schizophrenia showed significantly
lower education years (P < 0.001) and JART-based pre-
morbid IQ (P < 0.001) and a significantly higher rate ofcurrent smoking (P = 0.015) than controls. They were
found to have significantly lower performance in all cog-
nitive domains as measured with the z-scores of the six
BACS-J subtests (P < 0.001).
The characteristics of the selected five tagging SNPs
(rs4822724, rs61276843, rs9608491, rs713998, and
rs2014410) are shown in Table 2. All SNPs were in
Hardy–Weinberg equilibrium (all P > 0.001), and they
had minor allele frequencies greater than 10% in both
groups. The standard LD measures, denoted as pair-wise
D’ and r2 measures between markers in the HPS4 gene,
are illustrated in Additional file 1: Figure S1. For all
SNPs, there were no significant differences in age, sex,
education years, rates of current smoking, JART-based
premorbid IQs, ages at onset, prescription status of anxi-
olytics/hypnotics, PANSS scores (positive scores, nega-
tive scores, general psychopathology scores, and total









1 rs4822724 (A/G) 5′-flanking region Cases 0.0139 0.488
Controls 0.2472 0.485
2 rs612768431 (Del/Ins) 5′-flanking region Cases 0.3959 0.133
Controls 1.0000 0.121
3 rs9608491 (T/C) intron 4 Cases 1.0000 0.179
Controls 0.0569 0.188
4 rs713998 (G/A) exon 9 (p.G229E) Cases 0.1517 0.233
Controls 0.8529 0.225
5 rs2014410 (C/G) exon 11 (p.L443V) Cases 0.1900 0.271
Controls 0.0014 0.285
121-base deletion/insertion (Del/Ins) polymorphism.
HWE: Hardy–Weinberg equilibrium test.
MAF: minor allele frequency.
Kuratomi et al. BMC Psychiatry 2013, 13:276 Page 5 of 11
http://www.biomedcentral.com/1471-244X/13/276scores) between the genotype groups in the patients with
schizophrenia (Additional file 2: Table S1 and Additional
file 3: Table S2). The dosage of antipsychotics showed a
significant difference between the rs9608491 genotype
groups (P = 0.024), and the dosage of anticholinergics
showed a significant difference between the rs713998
genotype groups (P = 0.031). The other SNP genotype
groups showed no significant effects on the dosages of
antipsychotics or anticholinergic drugs. In controls,
there were no significant differences in any of the demo-
graphic characteristics (age, sex, education years, rates of
current smoking, and JART scores) between the geno-
type groups of all SNPs (Additional file 4: Table S3).
The associations between each tagging SNP in HPS4
and the cognitive domains that were measured by the
BACS-J subtests in the patients with schizophrenia are
shown in Table 3. Under the dominant model, rs713998
showed a significant association with executive function,
and this association remained after correction for mul-
tiple testing by Bonferroni correction (β = 0.319, t =
3.191, permutation P value = 0.0073). Under this domin-
ant model of rs713998, there was no significant differ-
ence in dosage of anticholinergics. The patients with a
minor allele carrier (A/A and A/G = −1.21 ± 1.98, mean ±
standard deviation) in rs713998 had a significantly higher
z-score of executive function than patients with major
allele homozygotes (G/G = −2.14 ± 2.36). In addition,
rs713998 showed a nominally significant (P < 0.05) associ-
ation with verbal memory, and this association did not re-
main after Bonferroni correction (verbal memory subtest
score: A/A and A/G = −1.74 ± 1.28, G/G = −2.19 ± 1.31, β =
0.210, t = 2.704, permutation P value = 0.029). There was
no significant difference between the HPS4 SNPs and the
cognitive domains under the recessive model or the addi-
tive model in the patients with schizophrenia.In the controls (Table 4), rs9608491 and rs713998 were
significantly associated with working memory under the re-
cessive model, and these associations remained after correc-
tion for multiple testing with Bonferroni corrections
(rs9608491, β= 0.701, t = 3.875, permutation P value = 0.001;
rs713998, β=−0.646, t =−3.276, permutation P value =
0.0065). The healthy controls with minor homozygotes
(C/C = 0.72 ± 0.84) in rs9608491 had a higher z-score of
working memory than major allele carriers (T/T and C/T=
−0.04 ± 0.99). Conversely, the healthy controls with minor
homozygotes (A/A=−1.07 ± 0.96) in rs713998 had a lower
z-score of working memory than major allele carriers (G/G
and A/G= 0.05 ± 0.97). In addition, rs4822724 showed a
nominally significant association with motor speed, and this
association did not remain after Bonferroni correction
(motor speed subtest score: G/G= 0.32 ± 0.97, A/A and A/
G=−0.11 ± 0.99, β= 0.342, t = 3.027, permutation P value =
0.013). There was no significant difference between HPS4
SNPs and cognitive domains under the dominant model in
the healthy controls (P > 0.05). Under the additive model,
the associations of working memory with the rs4822724,
rs9608491, and rs713998 genotypes were nominally signifi-
cant, and these associations did not remain after Bonferroni
corrections on the additive model (z-scores of working
memory subtest : rs4822724, G/G= 0.24 ± 0.93, A/G= 0.03
± 0.97, A/A=−0.27 ± 1.06, β= 0.148, t = 2.574, permutation
P value = 0.047; rs9608491, C/C= 0.72 ± 0.84, C/T =−0.06 ±
1.01, T/T=−0.04 ± 0.99, β= 0.209, t = 2.934, permutation
P value = 0.017; rs713998, A/A=−1.07 ± 0.96, A/G=−0.08
± 0.93, G/G= 0.13 ± 0.99, β=−0.217, t =−3.050, permutation
P value = 0.011).
Haplotype association analysis with cognitive functions
Additional file 5: Table S4 shows the global test scores
for the associations of the 2–5 locus haplotypes con-
structed according to the sliding window approach with
individual cognitive domains in the patients with schizo-
phrenia and the healthy controls. When the five tagging
SNPs (rs4822724, rs61276843, rs9608491, rs713998, and
rs2014410) were denoted with serial SNP numbers (1, 2,
3, 4, and 5), haplotype 3–4 and 2-3-4 showed significant
associations with working memory in the healthy con-
trols, and these remained after correction for multiple
testing with a Bonferroni correction (3–4: t = 14.9, per-
mutation global P value = 0.0025; 2-3-4: t = 15.0, permu-
tation global P value = 0.0064). The other haplotypes,
except for haplotype 1–2, showed nominal associations
with working memory (permutation global P value for
each haplotype: 2–3, 0.017; 4–5, 0.012; 1-2-3, 0.030; 3-4-5,
0.011; 1-2-3-4, 0.018; 2-3-4-5, 0.013; 1-2-3-4-5, 0.031).
The haplotype-specific tests of 3–4 and 2-3-4, which ful-
filled the criteria for significance in the global haplotype
test, with working memory were performed in the healthy
controls (Table 5). In haplotype 3–4, T-A and C-G showed
Table 3 Association of HPS4 SNPs with cognitive domains measured by the BACS-J in patients with schizophrenia
Cognitive domain SNP Dominant model Recessive model Additive model
β t P (perm) β t P (perm) β t P (perm)
Verbal memory rs4822724 -0.028 -0.296 0.999 -0.031 -0.323 0.998 -0.023 -0.388 0.991
rs61276843 0.183 2.062 0.165 0.275 1.120 0.757 0.164 2.139 0.131
rs9608491 -0.040 -0.489 0.989 0.147 0.644 0.967 -0.016 -0.226 0.999
rs713998 0.210 2.704 0.029 0.097 0.644 0.967 0.146 2.386 0.074
rs2014410 -0.128 -1.651 0.360 -0.236 -1.388 0.569 -0.123 -1.912 0.212
Working memory rs4822724 0.183 1.882 0.243 -0.026 -0.255 1.000 0.065 1.037 0.746
rs61276843 0.024 0.259 1.000 -0.123 -0.474 0.992 0.006 0.076 1.000
rs9608491 0.117 1.370 0.554 0.254 1.063 0.797 0.115 1.535 0.406
rs713998 0.068 0.824 0.896 -0.091 -0.580 0.982 0.026 0.408 0.988
rs2014410 -0.012 -0.141 1.000 -0.313 -1.753 0.329 -0.053 -0.781 0.888
Motor speed rs4822724 0.043 0.356 0.997 0.110 0.883 0.887 0.059 0.770 0.895
rs61276843 -0.079 -0.685 0.951 0.038 0.118 1.000 -0.056 -0.555 0.969
rs9608491 0.193 1.830 0.260 0.290 0.983 0.838 0.177 1.912 0.215
rs713998 -0.081 -0.797 0.910 0.093 0.476 0.992 -0.035 -0.430 0.988
rs2014410 0.069 0.683 0.952 -0.169 -0.763 0.936 0.024 0.280 0.998
Verbal fluency rs4822724 -0.087 -0.680 0.947 -0.036 -0.272 1.000 -0.049 -0.601 0.956
rs61276843 0.061 0.500 0.987 -0.066 -0.196 1.000 0.039 0.371 0.993
rs9608491 0.047 0.421 0.993 0.026 0.083 1.000 0.039 0.394 0.991
rs713998 0.152 1.412 0.524 0.210 1.016 0.820 0.129 1.530 0.419
rs2014410 -0.050 -0.473 0.989 -0.102 -0.432 0.995 -0.050 -0.559 0.966
Attention rs4822724 -0.075 -0.917 0.855 0.016 0.181 1.000 -0.025 -0.473 0.982
rs61276843 0.065 0.815 0.903 0.099 0.453 0.994 0.058 0.847 0.858
rs9608491 0.045 0.625 0.965 0.094 0.464 0.993 0.044 0.692 0.924
rs713998 0.123 1.778 0.294 0.125 0.937 0.870 0.097 1.785 0.265
rs2014410 -0.051 -0.738 0.932 -0.132 -0.871 0.897 -0.055 -0.948 0.803
Executive function rs4822724 -0.132 -1.096 0.740 -0.132 -1.057 0.798 -0.104 -1.352 0.522
rs61276843 0.257 2.242 0.111 -0.373 -1.169 0.730 0.156 1.561 0.390
rs9608491 -0.054 -0.511 0.985 -0.150 -0.506 0.991 -0.056 -0.606 0.953
rs713998 0.319 3.191 0.0073* -0.050 -0.259 1.000 0.188 2.377 0.080
rs2014410 -0.101 -1.002 0.797 -0.251 -1.133 0.752 -0.107 -1.269 0.578
Linear regression analyses were performed with the covariates of age, sex, education years, and JART scores. Permutation P-values, P (perm), were adjusted for
multiple testing between SNPs by each BACS-J subtest P-values < 0.0083 (0.05/6) were considered as statistically significant to correct for the number of BACS-J
subtests. P-values < 0.05 are in bold, and statistically significant results are marked with ‘*’.
BACS-J: Brief Assessment of Cognition in Schizophrenia, Japanese-language version.
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working memory (T-A: β = −0.216, t = 9.30, permutation
specific P value = 0.0074; C-G: β = 0.209, t = 8.61, permu-
tation specific P value = 0.011). In haplotype 2-3-4, Del-C-
G showed a significant positive effect on working memory
(Del-C-G: β = 0.209, t = 8.61, permutation specific P value
= 0.014). Del-C-G and C-G occurred at comparable fre-
quencies, as did Del-T-G and T-G, indicating that haplo-
type 2-3-4 containing the major allele (G) at rs713998 was
tagged most effectively by the major allele (del) at
rs61276843. These associations remained significant after
Bonferroni correction [P < 0.025 (0.05/2)] for multipletesting of the two classes (3–4 and 2-3-4) of the tested
haplotypes.
Discussion
In the present study, which was based on our previous
reports indicating an association of HPS4 with schizo-
phrenia [17], we evaluated the associations of HPS4 with
the clinical profiles of patients with schizophrenia and
the cognitive functions of patients with schizophrenia
and healthy controls. The major findings of our study
were as follows: (1) the HPS4 rs713998 polymorphism
was significantly associated with executive function in
Table 4 Association of HPS4 SNPs with cognitive domains measured by the BACS-J in healthy controls
Cognitive domain SNP Dominant model Recessive model Additive model
β t P (perm) β t P (perm) β t P (perm)
Verbal memory rs4822724 0.075 0.870 0.873 0.147 1.670 0.380 0.081 1.539 0.402
rs61276843 -0.071 -0.777 0.913 -0.072 -0.208 1.000 -0.065 -0.767 0.890
rs9608491 0.029 0.352 0.997 0.303 1.798 0.304 0.064 0.975 0.778
rs713998 -0.134 -1.724 0.317 -0.124 -0.675 0.967 -0.111 -1.700 0.310
rs2014410 0.014 0.182 1.000 0.010 0.085 1.000 0.009 0.169 1.000
Working memory rs4822724 0.225 2.412 0.069 0.174 1.793 0.313 0.148 2.574 0.047
rs61276843 -0.150 -1.494 0.459 -0.882 -2.361 0.086 -0.181 -1.961 0.193
rs9608491 0.162 1.797 0.283 0.701 3.875 0.001* 0.209 2.934 0.017
rs713998 -0.187 -2.202 0.120 -0.646 -3.276 0.0065* -0.217 -3.050 0.011
rs2014410 -0.069 -0.824 0.893 0.096 0.747 0.945 -0.014 -0.236 0.999
Motor speed rs4822724 0.085 0.764 0.921 0.342 3.027 0.013 0.155 2.274 0.095
rs61276843 -0.179 -1.502 0.458 -0.280 -0.626 0.973 -0.169 -1.539 0.399
rs9608491 0.045 0.417 0.994 0.159 0.722 0.951 0.052 0.613 0.951
rs713998 -0.127 -1.259 0.627 -0.271 -1.139 0.749 -0.126 -1.475 0.439
rs2014410 -0.090 -0.897 0.863 -0.075 -0.495 0.992 -0.062 -0.869 0.844
Verbal fluency rs4822724 -0.048 -0.487 0.989 0.051 0.500 0.991 -7.1 × 10-5 -0.001 1.000
rs61276843 -0.217 -2.084 0.168 -0.574 -1.469 0.522 -0.219 -2.287 0.092
rs9608491 -0.149 -1.594 0.402 0.062 0.321 1.000 -0.086 -1.145 0.664
rs713998 -0.171 -1.935 0.221 -0.160 -0.763 0.942 -0.143 -1.911 0.213
rs2014410 0.174 1.993 0.199 0.051 0.379 0.998 0.099 1.590 0.373
Attention rs4822724 0.090 1.171 0.697 0.063 0.793 0.929 0.057 1.199 0.629
rs61276843 -0.141 -1.718 0.326 -0.359 -1.168 0.728 -0.141 -1.873 0.226
rs9608491 0.062 0.842 0.892 0.229 1.508 0.481 0.074 1.257 0.585
rs713998 -0.044 -0.629 0.962 -0.226 -1.378 0.575 -0.060 -1.026 0.744
rs2014410 -0.008 -0.116 1.000 -0.035 -0.335 0.998 -0.004 -0.074 1.000
Executive function rs4822724 0.003 0.032 1.000 0.039 0.381 0.997 0.015 0.248 0.998
rs61276843 -0.049 -0.468 0.987 0.183 0.464 0.993 -0.031 -0.316 0.996
rs9608491 0.003 0.035 1.000 -0.066 -0.339 0.998 -0.008 -0.104 1.000
rs713998 0.020 0.229 1.000 0.099 0.470 0.993 0.027 0.363 0.993
rs2014410 -0.049 -0.558 0.976 -0.057 -0.423 0.996 -0.037 -0.594 0.954
Linear regression analyses were performed with the covariates of age, sex, education years, and JART scores. Permutation P-values, P (perm), were adjusted for
multiple testing between SNPs by each BACS-J subtest P-values < 0.0083 (0.05/6) were considered as statistically significant to correct for the number of BACS-J
subtests. P-values < 0.05 are in bold, and statistically significant results are marked with ‘*’.
BACS-J: Brief Assessment of Cognition in Schizophrenia, Japanese-language version.
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morphisms (rs9608491 and rs713998) and haplotypic
variants (rs9608491-713998 and rs61276843-9608491-
713998) in HPS4 were significantly associated with
working memory in Japanese healthy controls. These
significances survived after corrections for multiple test-
ing. Associations of the clinical profiles of patients with
schizophrenia (PANSS scores, ages at onset, and pre-
morbid IQs as measured by JART) with each SNP in
HPS4 were not observed.
Culminating lines of evidence have suggested that pa-
tients with schizophrenia show deficits of executivefunction, which is mainly mediated by the frontal lobe
and which is involved in the ability of goal formation,
planning, executing goal-directed plans, and effective
performance [4,54]. The TOL task, which was employed
as a task in order to assess executive function in the
BACS [3], is known to be involved in multifaceted as-
pects of executive function, including working memory,
planning, problem-solving, and inhibition [55,56]. Task
complexity in performing the TOL correlated with acti-
vation of the dorsolateral prefrontal cortex, the lateral
premotor cortex, the rostral anterior cingulate cortex,
and the right dorsal caudate nucleus in a positron
Table 5 Association of working memory with specific
haplotypes of HPS4 in healthy controls
Haplotype1 Frequency β t Specific P (perm)
3-4 T-G 0.588 0.005 0.008 0.996
T-A 0.225 -0.216 9.30 0.0074*
C-G 0.187 0.209 8.61 0.011*
2-3-4 Del-T-G 0.585 0.006 0.012 0.999
Del-C-G 0.187 0.209 8.61 0.014*
Del-T-A 0.107 -0.194 4.11 0.141
Ins-T-A 0.118 -0.180 3.75 0.171
Haplotype-specific tests with general linear models were performed with the
covariates of age, sex, education years, and JART scores. Permutation specific
P-values, specific P (perm), were adjusted for multiple testing between
individual haplotypes at the given locus P-values < 0.025 (0.05/2) were
considered as statistically significant to correct for the number of tested
haplotypes (3–4 and 2-3-4). P-values < 0.05 are in bold, and statistically
significant results are marked with ‘*’.
1SNP numbers are as follows: 2 = rs61276843, 3 = rs9608491, 4 = rs713998.
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Moreover, decreased prefrontal activation during the
TOL has been reported in subjects with first-episode
schizophrenia [58]. We showed that the minor allele A
that is carried at rs713998 was significantly associated
with higher performance in executive function that was
measured by the TOL task in patients with schizophre-
nia under the dominant genetic model, but there was no
association between any of the HPS4 SNPs and executive
function in healthy controls. Because the sample size,
age, and percentage of males were almost comparable
between the patients with schizophrenia and the healthy
controls, these results suggested that the rs713998 poly-
morphism confers distinct properties in frontal cortex-
mediated executive function, specifically in patients with
schizophrenia.
HS4 is unique in binding to the counterpart protein
HPS1 and in forming a 1:1 heterodimer called BLOC-3
that is involved in late endosomal trafficking [14,15,33].
Both the N-terminal (amino acid: 1–274) and C-terminal
domains (534–708) of HPS4 have been found to be re-
quired for assembly with a full-length HPS1 to form a sol-
uble and stable BLOC-3 complex [34]. Rs713998 is a
nonsynonymous SNP that is located in exon 9 (p.G229E)
and that has been reported to be completely linked with
three other nonsynonymous SNPs (rs5752330: exon 11, p.
M552V; rs1894706: exon 12, p.Y606H; rs1894704: exon
13, p.H625G) of HPS4 [17]. Given that the four SNPs
(rs713998, rs5752330, rs1894706, and rs1894704) that
completely link with each other occur in domains that are
required for HPS1–HPS4 interaction (N-terminal domain:
rs713998; C-terminal domain: rs5752330, rs1894706, and
rs1894704), it is plausible that the amino-acid substitu-
tions that are caused by these SNPs affect the HPS1–
HPS4 interactions and BLOC-3 complex stability. The
HPS1-HPS4 interaction is also indispensable for therecently identified function of BLOC-3 as a guanine nu-
cleotide exchange factor (GEF) for the small GTPases
Rab32/38 [35]. Although the longin domain that was
bioinformatically predicted to occur in the N-terminal
portion of HPS4 may be implicated in Rab GEF activity
[35], no exonic tagging SNP corresponding to this domain
was included in the present study.
Working memory impairments have been consistently
reported in patients with schizophrenia, even those with
first-episode schizophrenia with highly preserved IQ
[59]. A digit-sequencing task, which has been employed
as a task for assessing working memory in BACS [3], is
akin to a number-letter sequencing task. The latter was
found to activate the dorsolateral prefrontal cortex, the
orbital frontal lobe, the premotor cortex, and the poster-
ior parietal cortex, mainly in the right hemisphere, in a
positron emission tomographic study of healthy subjects
[60]. An SNP-based association analysis that was con-
ducted under the recessive model and a haplotype-based
association analysis have consistently shown that the C-
allele at rs9608491 and the G-allele at 713998 conferred
high performance in working memory in healthy con-
trols. Rs9608491 would contribute to a greater propor-
tion of the effect of this two-marker haplotype in the
performance of working memory in this population due
to its higher regression coefficient and smaller P value
(β = 0.701, P value = 0.001) than rs713998 under the re-
cessive model. However, the finding of the involvement
of rs713998 in working memory is apparently paradox-
ical because rs713998 at the A-allele state exerts a bene-
ficial effect on executive function in patients with
schizophrenia. Thus, working memory and executive
function that is measured by the TOL may reflect differ-
ent aspects of cognition, even though they are intimately
related to each other, and rs713998 may exert its effects
on these cognitive subdomains across controls and pa-
tients. Moreover, the finding that two alleles carried at
rs713998 showed differential effects on cognitive aspects
in cases versus controls could indicate a kind of ceiling
effect that cannot be accounted for by a simple dose–re-
sponse relationship of the alleles. For example, it has
been suggested that the catechol-O-methyltransferase
Val158Met polymorphism has an opposite effect on ver-
bal fluency in healthy controls compared with patients
with schizophrenia [61]. In patients with schizophrenia,
there has been no association of working memory with
any polymorphism or haplotype that has been examined
in HPS4, although medication and clinical symptoms
may have the potential to obscure any effects of genetic
variance. We previously found that protective haplotypes
always contained the C-allele carried at rs9608491 in HPS4
in a case–control study [17]. As discussed in our previous
study [17], an argument for the involvement of variants of
HPS4, particularly rs9608491, in the susceptibility to
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C-allele at rs9608491 may have a certain role in protecting
against the susceptibility to schizophrenia and in enhan-
cing working memory performance in controls only.
Very little information has thus far been found regard-
ing the neurobiological and behavioral aspects of HPS4,
although it is ubiquitously expressed in most tissues, in-
cluding brain [11]. To the best of our knowledge, the
Allen Brain Atlas [62] has only shown that HPS4 is
expressed in the hippocampal formation, the olfactory
areas, the cortical subplate, and the cerebellum of the
male adult mouse using in situ hybridization. Notwith-
standing the uncertainty about the role of this gene in
these brain regions, the data obtained here regarding the
association between rs9608491 and working memory
suggested that HPS4 plays a certain role in working
memory that is driven by the appropriate function of the
prefrontal cortex. Further analysis is required to reveal a
putative role of HPS4 in the neurobiology related to the
cognitive deficits in schizophrenia.
Several limitations of the present study must be men-
tioned. First, although the total sample size was moderate
for an association study of cognitive functions, a relatively
small number of individuals were included as carriers of
minor homozygotes for each SNP, except for rs4822724.
This could have resulted in a selection bias and decreased
the power under the recessive model when individuals
carrying the minor homozygotes were assigned to a dis-
tinct group. The associations of working memory with
rs9608491 and rs713998 in the healthy controls was re-
vealed by the recessive model, which yielded a minor
homozygote group with a small number of individuals
(rs9608491 C/C, n = 13; rs713998 A/A, n = 11). Replica-
tion of these findings in an independent large cohort or in
different ethnic cohorts is needed. Second, several lines of
evidence have indicated that cognitive performance in pa-
tients with schizophrenia is influenced by psychopharma-
cological medications [63,64]. In our positive finding of an
association between rs713998 and executive function in
patients with schizophrenia, we confirmed there was no
significant difference (P > 0.05) in the dosages of antipsy-
chotics, anticholinergics, or the prescription status of anxi-
olytics/hypnotics under the dominant model. However, in
a real-world clinical setting, the extent to which various
kinds of antipsychotics or their combination, particularly
in the context of the polypharmacy of antipsychotic medi-
cation, exerts an effect, if any, on the cognitive perform-
ance of patents with schizophrenia is difficult to analyze.
Third, rs9608491 is an intronic SNP located in between
the exons encoding the N-terminal domain. Its function is
uncertain because it is unlikely to affect the stability of
HPS4 mRNA [17]. This is reminiscent of the relevant
SNPs of the DTNBP1 gene, which are mostly intronic and
have been significantly implicated in the executivefunction of healthy controls [30], in cases belonging to
early-onset families with functional psychosis disorders
[65], and in the spatial working memory in patients with
schizophrenia [66]. This general aspect regarding the
question as to why intronic SNPs are involved in cognitive
function awaits further genetic study.
Conclusions
Our present study demonstrated that genetic variants in
HPS4 were associated with executive function in patients
with schizophrenia and with working memory in healthy
controls. To the best of our knowledge, this is the first
report of an association of HPS4 with cognitive func-
tions and the first to employ the BACS-J as a battery in
a SNP- and haplotype-based association study of cogni-
tive functions. Our present results suggested that HPS4
may be involved in the executive function deficits of pa-
tients with schizophrenia. Further research is needed to
elucidate the role of HPS4 in higher brain functions
through neurobiological and behavioral analyses of ani-
mal models.
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